Distortion Product Otoacoustic Emissions in Cisplatin Administered Patients

Abstract

Effect of antineoplastic agent, cisplatin (CDDP) on distortion product otoacoustic emissions (DPOAE) were measured in 4 young patients without any ear problems. All of them had orthopedic malignancies and had repeated CDDP administrations during the DPOAE measuring program. Dose dependent decrease of DPOAE level, especially in high frequencies and in low input primary levels, and partial recovery of them were obserued, where no apparent change in pure tone audiometry was detected. Although some limitations exist, early detection of cochlear damage by CDDP and other ototoxic agents is possible by DPOAE measurements. Further study to find better indexes that should reflect state of cochlear damage is necessary to make this method an easy and useful clinical indicator of ototoxicity.